Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Abstract Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible tyrosine kinase inhibitor with structural specificity for the catalytic domain...

Full description

Bibliographic Details
Main Authors:	Petros D. Grivas, Kathleen C. Day, Andreas Karatsinides, Alyssa Paul, Nazia Shakir, Iya Owainati, Monica Liebert, Lakshmi P. Kunju, Dafydd Thomas, Maha Hussain, Mark L. Day
Format:	Article
Language:	English
Published:	BMC 2013-10-01
Series:	Molecular Medicine
Subjects:	Dacomitinib Bladder Cancer Xenografts Non-obese Diabetic/severe Combined Immunodeficiency (NOD/SCID) Epidermal Growth Factor Receptor (EGFR) Lapatinib
Online Access:	https://doi.org/10.2119/molmed.2013.00108

Similar Items

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
by: Jinyao Zhang, et al.
Published: (2021-12-01)

Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
by: Leydis Luna Torres, et al.
Published: (2021-10-01)

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
by: Wen-Chien Cheng, et al.
Published: (2024-02-01)

Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib
by: Jian Liu, et al.
Published: (2024-01-01)

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
by: Bo Zhang, et al.
Published: (2022-03-01)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
by: Lavacchi D, et al.
Published: (2019-09-01)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
by: Qian Shen, et al.
Published: (2021-12-01)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
by: Ayako Morita, et al.
Published: (2021-04-01)

Bevacizumab plus dacomitinib combination therapy for L858R‐mutated metastatic lung adenocarcinoma: A report of two cases
by: Chi‐Kang Teng, et al.
Published: (2022-05-01)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
by: Xingxiang Pu, et al.
Published: (2023-10-01)

Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells
by: Ye Jin Lim, et al.
Published: (2024-01-01)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
by: Yibin Li, et al.
Published: (2022-08-01)

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China
by: Hong-Shuai Li, et al.
Published: (2022-06-01)

Use of Hu-PBL Mice to Study Pathogenesis of Human-Restricted Viruses
by: Jesús Emanuel Brunetti, et al.
Published: (2023-01-01)

Recent Developments in NSG and NRG Humanized Mouse Models for Their Use in Viral and Immune Research
by: Maksym Kitsera, et al.
Published: (2023-02-01)

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment
by: Hong-Shuai Li, et al.
Published: (2021-04-01)

Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon <i>EGFR</i> Mutations: A Comparative Cohort Study in China (AFANDA Study)
by: Hong-Shuai Li, et al.
Published: (2022-10-01)

A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
by: Manal A. Alossaimi, et al.
Published: (2023-03-01)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
by: Ikei S. Kobayashi, et al.
Published: (2021-12-01)

Lapatinib-Loaded Nanocapsules Enhances Antitumoral Effect in Human Bladder Cancer Cell
by: Julieti Huch Buss, et al.
Published: (2019-04-01)

Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo
by: Xiaoran Guo, et al.
Published: (2018-02-01)

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)
by: Hisashi Tanaka, et al.
Published: (2022-05-01)

Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial
by: Masahiro Iwasaku, et al.
Published: (2023-07-01)

Establishment and Its Biological Characteristics of Patient-derived Lung Cancer Xenograft Modelse
by: Ying ZHUO, et al.
Published: (2010-06-01)

One Host-Multiple Applications: Zebrafish (<i>Danio rerio</i>) as Promising Model for Studying Human Cancers and Pathogenic Diseases
by: Karolina Dudziak, et al.
Published: (2022-09-01)

Synergistic Antitumor Activity and Mechanism of Lapatinib and Paclitaxel in Esophageal Cancer Cells
by: CHEN Tao, et al.
Published: (2021-01-01)

Antitumor Efficacy and Mechanisms of Lapatinib in Combination with Cisplatin on Esophageal Squamous Cancer Cells
by: DOU Qiaohua, et al.
Published: (2019-09-01)

A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations
by: Hong‐Shuai Li, et al.
Published: (2022-02-01)

Drug-induced liver injury associated with dacomitinib: A case report
by: Xuanxuan Wang, et al.
Published: (2022-09-01)

Establishment of a Spontaneous Liver Fibrosis Model in NOD/SCID Mice Induced by Natural Aging
by: Lihua Qiu, et al.
Published: (2023-12-01)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
by: Hui Zhang, et al.
Published: (2022-04-01)

The development and improvement of immunodeficient mice and humanized immune system mouse models
by: Jiaxuan Chen, et al.
Published: (2022-10-01)

Long Term Amperometric Recordings in the Brain Extracellular Fluid of Freely Moving Immunocompromised NOD SCID Mice
by: Caroline H. Reid, et al.
Published: (2017-02-01)

Comparison between NOD/SCID mice and BALB/c mice for patient-derived tumor xenografts model of non-small-cell lung cancer
by: Wu J, et al.
Published: (2018-12-01)

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
by: Freeman Daniel J, et al.
Published: (2012-07-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells
by: Christine E. Lehman, et al.
Published: (2019-01-01)

Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer
by: George D. Wilson, et al.
Published: (2021-01-01)

Different chemical proteomic approaches to identify the targets of lapatinib
by: Tatjana Kovačević, et al.
Published: (2023-12-01)